CEREBROSPINAL-FLUID S-ADENOSYLMETHIONINE IN DEPRESSION AND DEMENTIA - EFFECTS OF TREATMENT WITH PARENTERAL AND ORAL S-ADENOSYLMETHIONINE

Cerebrospinal fluid (CSF) S-adenosyl-methionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise in CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.